First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials

INTRODUCTION: ) mutation. Chemotherapy (ChT) given in combination with an EGFR-TKI in this setting is of interest. METHODS: mutation. RESULTS: < 0.00001). CONCLUSIONS: -mutated NSCLCs, the EGFR-TKI + ChT combination, compared to EGFR-TKI alone, was associated with significantly prolonged PFS and OS. However, further studies are needed to identify which patients will benefit the most from the combination. REGISTRATION: PROSPERO CRD42024508055.